Evidence map›Paper›PMID 23017510›Full record

Trial reportThe Journal of urology2013

Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms.

Michael J Barry, Alan Cantor, Claus G Roehrborn, CAMUS Study Group

Open access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 6 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 6 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Lower urinary tract symptoms in men: the TRIUMPH cluster RCT.Health technology assessment (Winchester, England) · 2024
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Michael J BarryMassachusetts General Hospital, Boston, Massachusetts 02114, USA. mbarry@partners.org
Alan Cantor
Claus G Roehrborn
CAMUS Study Group
Massachusetts General Hospital · USThe University of Texas Southwestern Medical Center · USUniversity of Alabama at Birmingham · US

Funding

Data Coordinating Center for Benign Prostate SymptomsU01DK063788 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CANTOR, ALAN B. · 2002 to 2011
$5.4M
Phytotherapy for Benign Prostatic HyperplasiaU01DK063795 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI AVINS, ANDREW L · 2002 to 2010
$1.6M
Phythotherapy for the Treatment of BPH SymptomsU01DK063862 · NIDDK · YALE UNIVERSITY · PI FOSTER, HARRIS E · 2002 to 2010
$1.6M
Alternative Therapies for Benign Prostate SymptomsU01DK063840 · NIDDK · UNIVERSITY OF IOWA · PI KREDER, KARL J · 2002 to 2011
$1.5M
Alternative Therapies for BPH, Multiethnic VariablilityU01DK063831 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI KAPLAN, STEVEN A · 2002 to 2010
$1.4M
ALTERNATIVE THERAPIES FOR BENIGN PROSTATIC SYMPTOMSU01DK063778 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI NASLUND, MICHAEL J · 2002 to 2010
$1.4M
Saw palmetto and Pygeum africanum on BPH ProgressionU01DK063866 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCVARY, KEVIN T. · 2002 to 2010
$1.3M
Alternate Therapies for Benign Prostate SymptomsU01DK063835 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI ROEHRBORN, CLAUS G · 2002 to 2010
$1.3M
Alternative Therapies for Benign Prostate SymptomsU01DK063883 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MCCULLOUGH, ANDREW R · 2002 to 2010
$1.2M
Phytotherapy of Prostateic Symptoms (POPW)U01DK063833 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CRAWFORD, E DAVID · 2002 to 2010
$1.1M
Clinical Evaluation &Treatment Center for BPHU01DK063825 · NIDDK · WASHINGTON UNIVERSITY · PI ANDRIOLE, GERALD LOUIS · 2002 to 2011
$1.1M
Alternative Therapies for Benign Prostatic Hyperplasia (CAMUS)U01DK063797 · NIDDK · QUEEN'S UNIVERSITY AT KINGSTON · PI NICKEL, JOHN CURTIS · 2003 to 2010
$841k
NIDDK NIH HHS U01 DK063778NIDDK NIH HHS U01 DK063788NIDDK NIH HHS U01 DK063795NIDDK NIH HHS U01 DK063797NIDDK NIH HHS U01 DK063825NIDDK NIH HHS U01 DK063831NIDDK NIH HHS U01 DK063833NIDDK NIH HHS U01 DK063835NIDDK NIH HHS U01 DK063840NIDDK NIH HHS U01 DK063862NIDDK NIH HHS U01 DK063866NIDDK NIH HHS U01 DK063883NIDDK NIH HHS U01 DK63778NIDDK NIH HHS U01 DK63788NIDDK NIH HHS U01 DK63795NIDDK NIH HHS U01 DK63797NIDDK NIH HHS U01 DK63825NIDDK NIH HHS U01 DK63831NIDDK NIH HHS U01 DK63833NIDDK NIH HHS U01 DK63835NIDDK NIH HHS U01 DK63840NIDDK NIH HHS U01 DK63862NIDDK NIH HHS U01 DK63866NIDDK NIH HHS U01 DK63883
6 · The paper itself

Abstract

purposeWe related changes in American Urological Association symptom index scores with bother measures and global ratings of change in men with lower urinary tract symptoms who were enrolled in a saw palmetto trial. MATERIALS AND

methodsTo be eligible for study men were 45 years old or older, and had a peak uroflow of 4 ml per second or greater and an American Urological Association symptom index score of 8 to 24. Participants self-administered the American Urological Association symptom index, International Prostate Symptom Score quality of life item, Benign Prostatic Hyperplasia Impact Index and 2 global change questions at baseline, and at 24, 48 and 72 weeks.

resultsIn 357 participants global ratings of a little better were associated with a mean decrease in American Urological Association symptom index scores from 2.8 to 4.1 points across 3 time points. The analogous range for mean decreases in Benign Prostatic Hyperplasia Impact Index scores was 1.0 to 1.7 points and for the International Prostate Symptom Score quality of life item it was 0.5 to 0.8 points. At 72 weeks for the first global change question each change measure discriminated between participants who rated themselves at least a little better vs unchanged or worse 70% to 72% of the time. A multivariate model increased discrimination to 77%. For the second global change question each change measure correctly discriminated ratings of at least a little better vs unchanged or worse 69% to 74% of the time and a multivariate model increased discrimination to 79%.

conclusionsChanges in American Urological Association symptom index scores could discriminate between participants rating themselves at least a little better vs unchanged or worse. Our findings support the practice of powering studies to detect group mean differences in American Urological Association symptom index scores of at least 3 points.

Indexed as

HumansLower Urinary Tract SymptomsMaleMiddle AgedPhytotherapyPlant PreparationsProstatic HyperplasiaSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeUrinationPlant Preparations

Identifiers

PMID23017510
PMCPMC3932029
OpenAlexW2149824633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.